The Vasculitis Patient-Powered Research Network (V-PPRN): Conducting Studies to Improve Care for Vasculitis Patients

The goal of the Vasculitis Patient-Powered Research Network’s (V-PPRN) research program is to conduct high quality studies that will improve the care and the health of patients with vasculitis by exploring research questions that matter most to patients and advance medical knowledge about vasculitis. The Challenge All the different types…...

Read more

The Vasculitis Clinical Research Consortium is Dedicated to the Study of Vasculitis

The Vasculitis Clinical Research Consortium (VCRC) is the major clinical research infrastructure in North America dedicated to the study of vasculitis. The Vasculitis Clinical Research Consortium has grown to include 18 academic medical centers in the United States and Canada conducting investigator-initiated clinical and translational research. The Vasculitis Clinical Research…...

Read more

The Vasculitis Foundation Honors Glenn Kullman, a Devoted Volunteer

Arlene and Glenn Kullman Glenn Kullman, longtime Vasculitis Foundation volunteer, passed away in January after a brief battle with cancer. He was diagnosed with Wegener’s (now GPA), in October 1994. When Dr. Ann Warner, a rheumatologist, diagnosed him, she said, “You have a rare disease called Wegener’s granulomatosis. You’ve probably…...

Read more

Study: Patterns of Relapse in Vasculitis can be Similar or Completely Different

Peter Grayson, MD, at the 2017 Vasculitis Symposium By Kurt Ullman, Medical Writer Many physicians tend to look at relapses of complex diseases such as systemic vasculitis as mirroring the symptoms seen at the original diagnosis. However, this isn’t always the case. Understanding the frequency and types of a patient’s…...

Read more

GlaxoSmithKline (GSK) achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US

On December 13, 2017, GSK announced that the U.S. Food and Drug Administration (FDA) approved Nucala (mepolizumab) as the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome (CSS). The approval for EGPA is based on results from the pivotal, 52-week, Phase III MIRRA1 study,…...

Read more